Best Oncology Companies in Jerusalem District, Israel
The 31 best Oncology companies in Jerusalem District, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Gamida Cell.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Jerusalem District
| # | Company | Disclosed funding | Last round | Stage | Founder | Employees | Founded | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Gamida Cell Developer of cell therapies to treat cancer and other serious diseases | $139M | 111 mo ago | Public | Joseph Wiley CEO and Chairman | 146 | 1998 | 211 patents Cellular immunotherapy manufacturing: NK, gamma‑delta T, and umbilical‑cord stem cell products | — |
| 2 | NovellusDx Developer of technology for precision cancer diagnosis and therapies | $86M | 73 mo ago | Series C | — | 49 | 2011 | 46 patents Personalized oncology genomics: driver mutation identification, functional mutagenesis, drug response prediction. | — |
| 3 | KAHR Developer of immune therapeutics to treat cancer | $58M | 47 mo ago | Series D | Yaron Pereg CEO | 32 | 2005 | — | — |
| 4 | Illumigyn Developer of colonoscope for cervical cancer detection interventional procedures | $38M | 60 mo ago | Series B | Lior Greenstein Executive Board Member Founder Technology Advisor | 25 | 2014 | 38 patents Gynecological optical imaging and diagnostic devices for tissue inspection and abnormal cell removal | — |
| 5 | Vidac Pharma HK2-VDAC protein interaction disruptors for oncologic and oncodermatologic diseases. 21Product top 36%Growth top 45%Patents top 47%Moat top 47% All 9 signals ▾Producttop 36% Growthtop 45% Patentstop 47% Moattop 47% Innovationbottom 48% Fundingbottom 45% Techbottom 36% Globalbottom 35% Marketbottom 23% Product: 8 distinct product lines · Company stage: Series A Growth: Web rank 10,000,000 → 50,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 21/100 | $10M | 24 mo ago | Series A | — | 9 | 2011 | 44 patents Developing HK2‑targeted small‑molecule cancer therapeutics, especially piperazine‑based inhibitors. | — |
| 6 | Senseera Provider of liquid biopsy blood tests for cancer diagnosis 35Talent top 28%Funding top 46%Market bottom 37%Global bottom 36% All 4 signals ▾Talenttop 28% Fundingtop 46% Marketbottom 37% Globalbottom 36% Talent: 4 named leaders on record · 4 C-suite/founder profiles curated Funding: Raised $7.1M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $7M | 22 mo ago | Seed | Nir Friedman Co-Founder | — | 2020 | — | — |
| 7 | HIL Medical Developer of proton-beam radiotherapy device to treat solid tumors | $3M | 42 mo ago | Series C | Arie Zigler Co-Founder | — | 2010 | 42 patents Ion beam delivery systems and control methods for advanced particle cancer therapy | — |
| 8 | Eventus Diagnostics Immune system-based blood tests for the detection of breast cancer | $3M | 151 mo ago | Deadpooled | Marvin Rosenberg Co-Founder & President | — | 2010 | 5 patents Early cancer biomarker detection via nucleic acid assay methods | — |
| 9 | Tiltan Pharma Develops therapeutics for treatment of metastatic pancreatic cancer using combinatorial drug therapy… | $2M | 153 mo ago | Deadpooled | Yigal Stav CEO & Co-Founder | — | 2006 | 29 patents Oncological combination drug regimens, including non‑cytotoxic and H2‑blocker based therapies. | — |
| 10 | Immunovative Therapies Developing personalized vaccines and activated T cells for the treatment of cancer and infectious diseases. | $2M | 226 mo ago | Series A | — | 18 | 2004 | 287 patents Allogeneic Th1 cell immunotherapies and Treg inhibition for infectious disease treatment | — |
| 11 | BioMarCare Developer of biomarkers for cardiovascular disease risk assessment and management | $1M | 175 mo ago | Deadpooled | Dana Cohen Founder & CEO | 5 | 2009 | — | — |
| 12 | ISK Human secreted peptides for malignant and autoimmune diseases | $800K | 138 mo ago | Funding Raised | — | — | 2005 | — | — |
| 13 | LipoMedix Provider of Israeli clinical-stage biotech developing PEG-ylated liposomal Mitomycin drugs for cancer | $639K | 83 mo ago | Funding Raised | Alberto Gabizon Founder & CEO | — | 2011 | — | — |
| 14 | NIMD Noninvasive microwave heating technology for cancer treatment | $600K | 129 mo ago | Deadpooled | Anan Copty Co-Founder & CEO | — | 2015 | 3 patents Patents concentrated in health & consumer products | — |
| 15 | Marx Biotechnology Developer of molecular diagnostic kit for the early detection of Graft Versus Host Disease | $500K | 178 mo ago | Seed | Stephen Marx Founder & CEO | 3 | 2011 | — | — |
| 16 | Immunyx Developer of neutrophil therapies for multiple diseases | $269K | 53 mo ago | Funding Raised | Zvi Fridlender Co-Founder | 7 | 2021 | — | — |
Top 12 Oncology companies in Jerusalem District
#1
Seed · Jerusalem, Jerusalem District · founded 2020$7.1Mraised▾
Provider of liquid biopsy blood tests for cancer diagnosis. The cfChIP-seq technology can detect cell-free chromatin tissue which can be used to identify patient-specific gene expression for the detection of diseases and treatment response. The company uses molecular biology, next-generation sequencing, and computational analysis to extract epigenetic information.
- Jan 2025Seed$7.1M
#2
Series A · Jerusalem, Jerusalem District · founded 2011 · 9 employees$9.6Mraised▾
Vidac Pharma is focussed on developing medicines for a range of oncologic and oncodermatologic diseases. Its technology is based on modifying the HK2 (hexokinase enzyme)-VDAC (voltage-dependent anion channel) system which overexpresses in many cancer types. It is developing small molecule drugs which disrupt the protein interactions and can modulate this target for the selective apoptosis of cancer cells. Its lead product VDA-1102, a formulated topical ointment is being developed for actinic keratosis (phase 1 completed), Cutaneous Squamous Cell Carcinoma (phase 1) and Cutaneous Skin Lymphoma & solid tumors (pre-clinical). Besides, it is also developing VDA-1214, a systemic drug for treatment of solid tumors (pre-clinical).
- Nov 2024Series A$644.9K
- Jun 2016Series A$9M
#3
Series D · Jerusalem, Jerusalem District · founded 2005 · 32 employees$58.5Mraised▾
Developer of immune therapeutics to treat cancer. The company's product candidates include DSP107 SIRPα-41BBL, DSP105 PD1-41BBL, and TSPs TIGIT/LILRB/SIGLEC used for the treatment of solid tumour. The company has developed its proprietary MIRP (Multifunctional Immune Recruitment Protein) technology for the discovery of immuno-recruitment drugs. It is used to target the immune checkpoints for unmasking cancer camouflage mechanisms.
- Nov 2022Series D—
- May 2021Series C$46.5M
- Jan 2019Grant (prize money)$151.5K
- Dec 2015Series B$12M
#4
Series C · Jerusalem, Jerusalem District · founded 2011 · 49 employees$85.5Mraised▾
Developer of technology for precision cancer diagnosis and therapies. The company's technology allows monitoring the outcomes of known and unknown DNA mutations, the function & clinical significance of each mutation, and the activity of the drug(s) on a specific tumor.
- Sep 2020Series C$57M
- Apr 2018Series B$6M
- Jun 2016Series B$12.5M
- Dec 2015Series A$10M
#5
Series C · Jerusalem, Jerusalem District · founded 2010$3.1Mraised▾
Developer of proton-beam radiotherapy device to treat solid tumors. The company applies particle acceleration and beam delivery approach, combining nano-technology with ultra-high-intensity lasers and ultra-fast magnets to develop proton-therapy systems for cancer treatment.
- Apr 2023Grant (prize money)$55.1K
- Sep 2021Grant (prize money)$58.2K
- May 2021Grant (prize money)$1.8M
- Dec 2020Grant (prize money)$2M
#6
Series B · Jerusalem, Jerusalem District · founded 2014 · 25 employees$38Mraised▾
Developer of colonoscope for cervical cancer detection interventional procedures. The product Gynescope is a patented imaging colposcope coupled with multispectral illumination options that can be used for the early detection of cervical cancer. It also claims that the Gynescope is the only colposcope that allows the imaging with simultaneous complex interventional procedures to support the best clinical outcomes.
- Nov 2021Series B$33M
- Nov 2016Series A$5M
#7
Public · Jerusalem, Jerusalem District · founded 1998 · 146 employees$139.1Mraised▾
Developer of cell therapies to treat cancer and other serious diseases. The company is pioneering a proprietary NAM platform for allogeneic cell sources including umbilical cord blood-derived cells and NK cells to create therapies for solid tumors. The lead product of the company is omidubicel for the treatment of hematological malignancies.
#8
Deadpooled · Jerusalem, Jerusalem District · founded 2010$2.7Mraised▾
Eventus Diagnostics is focussed on developing blood-based tests for the detection of breast cancer. It has developed a CE-approved test called Octava which is an immune system-based blood test that detects the presence or absence of cancer by measuring ratios of autoantibodies produced in response to the presence of tumor-specific antigens. It has developed Octava Pink and Octava Blue tests which are designed to be used in conjunction with annual screening mammograms and can provide additional information that enables women and their physicians to better assess the validity of their mammography results.
- Apr 2014Series A$2.7M
- Feb 2012Conventional Debt$741.9K
#9
Funding Raised · Jerusalem, Jerusalem District · founded 2021 · 7 employees$268.7Kraised▾
Developer of neutrophil therapies for multiple diseases. It offers drug candidates IMYX-3 for respiratory diseases, IMYX-4 for inflammatory diseases, and IMYX-5 for cancer. It has a targeted neutrophil nanoparticle platform that modulates neutrophils.
- Jun 2022Grant (prize money)$268.7K
#10
Funding Raised · Jerusalem, Jerusalem District · founded 2011$638.8Kraised▾
Provider of Israeli clinical-stage biotech developing PEG-ylated liposomal Mitomycin drugs for cancer. The company's lead drug mitomycin-C, a chemotherapeutic agent, and its delivery in liposomes called Promitil – Pegylated Liposomal Mitomycin-C Prodrug (PL-MLP) for colon cancer.
- Nov 2019Grant (prize money)$55K
- Jul 2019Grant (prize money)$56.4K
- May 2016Grant (prize money)$527.3K
#11
Deadpooled · Jerusalem, Jerusalem District · founded 2006$1.5Mraised▾
Tiltan Pharma is a bio-pharmaceutical company that has developed a proprietary anti-angiogenic and immune modulatory technology, for the treatment of cancer. The company's leading product, TL-118, is an oral drug combination of anti-cancer, anti-angiogenic and immune modulatory properties. The drug is being evaluated for a phase IIb study for metastatic pancreatic cancer patients under an FDA approved IND. .
- Feb 2014PE$1.5M
#12
Series A · Jerusalem, Jerusalem District · founded 2004 · 18 employees$1.5Mraised▾
Immunovative Therapies is a clinical stage biopharmaceutical company specializing in the translation of proven immune mechanisms into immunotherapy products and protocols for treatment of cancer and infectious diseases. Its patented “Mirror Effect” technology provides an immunological platform for the development of drugs that elicit the same powerful antitumor and anti-HIV effects of bone marrow/stem cell transplant procedures while eliminating the side effects of the procedure and the need for a tissue-matched donor. It has two products in clinical development: AlloStim®, a bioengineered living cell allograft; and Chaperone-Rich Cell Lysate (CRCL), a patient-specific heat shock protein vaccine. AlloStim® cells are activated allogeneic Th1 memory T-cells containing cytolytic granules. CRCL is a source of patient-specific tumor antigens. AlloVax® is a therapeutic anti-cancer vaccine consisting of CRCL as the source of tumor antigen and AlloStim® as an adjuvant. The intradermal injection of AlloVax® elicits tumor-specific Th1 immunity.
- Jan 2008Series A$1.5M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Oncology & Cancer Therapeutics is moving in Israel
A read on the academic research around Oncology & Cancer Therapeutics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 263 Israel-affiliated papers.
- Tel Aviv University55
- Weizmann Institute of Science42
- Technion – Israel Institute of Technology42
- Hadassah Medical Center33
- Hebrew University of Jerusalem31
- Immune system2→40
- Tumor microenvironment5→42
- Cancer research6→30
- Immunotherapy1→24
- Cancer immunotherapy1→23
- Tumor microenvironment6→51
- Immune system3→37
- Cancer research2→30
- Immunotherapy2→30
- Melanoma2→8
- Tumor microenvironment1→11
- Immune system1→9
- Immunology1→4
- Cancer research1→4
Where oncology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.